Original Research

Drug-Induced Liver Injury in Critically Ill Children Taking Antiepileptic Drugs: A Retrospective Study

Kannan Sridharan, MD, DM1,∗, Amal Al Daylami, MRCP2, Reema Ajjawi, MD2, Husain A.M. Al Ajooz, MD2

1 Department of Pharmacology & Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
2 Pediatric Intensive Care Unit, Salmaniya Medical Complex, Ministry of Health, Manama, Bahrain

[Details of the article...]

Introduction

Antiepileptic and anticonvulsant agents are among the commonly used drug classes in intensive care units (ICUs). Antiepileptic drugs (AEDs) are also initiated in ICUs as prophylactic drugs in patients with traumatic brain injury, meningitis, and brain neoplasms.1 Febrile convulsions is a unique indication in children to receive anticonvulsant drugs in pediatric ICUs (PICUs).2 One-tenth of critically ill children were initiated AEDs acutely in ICU settings due to epileptic seizures.3 Almost 53% treated for a seizure attack were reported to have recurrent seizures in a PICU.3

Drug-induced liver injury (DILI) is defined as the xenobiotic-induced hepatic injury resulting in alteration of liver enzymes in the absence of other known causes.5 The majority of antiepileptic agents get metabolized in the liver and form a leading cause of DILI worldwide.6,7 DILI can range between asymptomatic elevations of liver enzymes and hepatic failure.8 Although hepatotoxicity is a common adverse event amongst the conventional AEDs, valproate has more hepatotoxicity than carbamazepine that...
has more than phenytoin.\textsuperscript{10} Children are particularly more susceptible to idiosyncratic hepatotoxicity than adults.\textsuperscript{11} Particularly, children younger than age 2 years are vulnerable to developing DILI following sodium valproate.\textsuperscript{8} Patients admitted in ICUs are more likely to be observed with abnormal liver enzymes due to several reasons such as acute hepatitis, acute liver failure, and secondary sclerosing cholangitis that are unrelated to antiepileptic agents but rather to their critical illnesses.\textsuperscript{12} Critically ill patients often have hypoxic, toxic, and inflammatory insults to the hepatocytes that can increase the risk of hepatotoxicity.\textsuperscript{13} LiverTox (https://livertox.nih.gov/) is a database conceptualized by the National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases and the Drug-Induced Liver Injury Network study group to provide evidence-based up-to-date details on DILI for practising clinicians and researchers working on this field.\textsuperscript{14} Based on the cumulative evidence available for drug-induced hepatotoxicity, LiverTox has classified drugs into categories A, B, C, D, and T.\textsuperscript{15} Categories A and B have substantial case reports with adequate strength of associating the implicated drugs with liver injury. DILI-rank is the largest reference rank dataset on drugs causing DILI, developed by the Food and Drug Administration (FDA) in the year 2016.\textsuperscript{16} DILIrank classifies 1036 FDA-approved drugs into most-, less-, and ambiguous-DILI-concern drugs. It is vital to understand the hepatotoxic potentials of concomitant drugs administered in ICU setup, particularly in critically ill children receiving categories A and B drugs according to LiverTox or most/less-DILI concerns as per DILIrank classification. We envisaged the present study to assess the changes in liver function tests associated with primary antiepileptic agents belonging to the above categories and the associated factors for DILI in these critically ill children.

## Methods

### Study ethics and population

This study was carried out as a retrospective observational study after obtaining approval from our institution’s ethics committee. Children admitted into the PICU between January 1, 2016, until December 31, 2018, were included in the study if they were administered any of the antiepileptic or anticonvulsant drugs with at least 1 assessment of serum liver enzyme levels and measurement of serum level of the concerned drug was carried out. Those children diagnosed without any primary liver disorders were included in this study.

### Study procedure

Hospital records of eligible children were examined for the following details: demographic characteristics (eg, age and gender); diagnoses; laboratory investigations (eg, liver enzymes that included serum aspartate amino transferase [AST], alanine amino transferase [ALT], alkaline phosphatase [ALP], and gamma glutamyl transferase [GGT]); drug-related details (eg, dose, frequency, and duration); hospital stay; and outcome status (eg, dead or alive).

### Definitions and classifications used

DILI has been classified according to the revised criteria by Council for International Organizations of Medical Sciences as follows: hepatocellular injury, ALT ≥2 upper limit of normal (ULN) reference range (RR) and R ≥5; cholestatic injury, ALP ≥2 ULN and R ≥2; mixed injury, ALT ≥3 ULN, ALP ≥2 ULN, and 2 <R< 5. If ALT and ALP did not meet any of these criteria, it was called liver biochemical test abnormalities.\textsuperscript{17} The value of R was calculated using the formula (actual ALT/ALT ULN) / (actual ALP/ALP ULN). Our laboratory provides age-specific reference ranges for liver function tests and these values were considered for assessing DILI.

LiverTox classifies the drugs based on the number of published cases with clear association with DILI into category A (≥50 cases); category B (12–49 cases); category C (4–11 cases); category D (1–3 cases), and category E (none). Those drugs that cause DILI only at higher than the recommended doses are categorized as T. Similarly, DILIrank classifies the drugs based on the reported concerns and severity of DILI. Table 1 lists the antiepileptic drugs based on the LiverTox and DILIrank categories. We classified ages of children per FDA classification into the following groups: neonate (birth–1 month), infant (1 month–2 years), children (2–12 years), and adolescents (12–16 years).\textsuperscript{15}

### Table 1

| Antiepileptic drug | LiverTox category | DILIrank classification |
|--------------------|-------------------|-------------------------|
| Carbamazepine      | A                  | Most                    |
| Clonazepam         | D                  | Less                    |
| Diazepam           | E                  | Ambiguous               |
| Divalproex sodium  | Not classified     | Ambiguous               |
| Ethosuximide       | E                  | Ambiguous               |
| Felbamate          | B                  | Most                    |
| Phenytoin          | A                  | Most                    |
| Gabapentin         | C                  | Less                    |
| Lacosamide         | Not classified     | Ambiguous               |
| Lamotrigine        | B                  | Most                    |
| Levetiracetam      | C                  | Less                    |
| Lorazepam          | Not classified     | Ambiguous               |
| Midazolam          | Not classified     | No                      |
| Oxcarbazepine      | D                  | Less                    |
| Phenytoin          | A                  | Most                    |
| Pregabalin         | C                  | Less                    |
| Primidone          | Not classified     | No                      |
| Tiagabine          | Not classified     | Ambiguous               |
| Topiramate         | C                  | Less                    |
| Valproate sodium   | A                  | Most                    |
| Vigabatrin         | Not classified     | Ambiguous               |
| Zonisamide         | D                  | Less                    |

* LiverTox (https://livertox.nih.gov/), a database conceptualized by the National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases and the Drug-Induced Liver Injury Network study group.

### Statistical analysis

Descriptive statistics was used for representing demographic characteristics. The $\chi^2$ test for independence and Fisher exact probability test were used for the assessment of categorical variables wherever appropriate. Concomitant drugs with potential hepatotoxicity were classified as per LiverTox classification and DILIrank, and were assessed as categorical outcomes. Multivariable logistic regression analysis was used to assess the significance of association between the predictor variables (ie, age group, sex, antiepileptic drug, and number of LiverTox categories A and B drugs) in causing DILI. Only A and B of LiverTox categories were considered because other categories have limited evidence for their association with DILI. A similar regression analysis was carried out for DILIrank categories with the same predictor variables, and only the most- and less-DILI-concern concomitant drugs were included. The effect measures of variables in predicting DILI were expressed as odds ratio (95% CI). A P value ≤0.05 was considered significant. SPSS version 26 (IBM SPSS Statistics for Windows, Armonk, NY) was used for performing statistical tests.
Results

Demographic details

Forty-one patients were identified receiving drugs for seizure disorder out of the total 426 during the study period. Mean (SD) age was 3.9 years (3.8 years); body weight was 15.1 kg (13 kg); and male:female ratio was 26:15. Six had refractory status epilepticus; 5 had septic encephalopathy; 4 each had traumatic brain injury and cerebral palsy; 3 each had hydrocephalus with ventriculoperitoneal shunt, encephalitis, and congenital heart disease; 2 each were diagnosed with hypoxic ischemic encephalopathy and metabolic disorder; and 1 each had astrocytoma with metastasis, glioblastoma, Treacher syndrome, DiGeorge syndrome, Down syndrome, hemophilia, chronic kidney disease on peritoneal dialysis, leukodystrophy, and metabolic disorder. Mean (SD) hospital stay of the study participants was 12.2 days (9.8 days).

Antiepileptic drug-related details

Eleven patients received phenytoin; 9 received phenobarbitone; 3 were administered valproate sodium; 10 children were administered phenytoin/phenobarbitone; 3 were given phenytoin/phenobarbitone/valproate sodium; and 1 each received phenytoin/valproate sodium, phenobarbitone/valproate and ethosuximide/valproate sodium, phenytoin/carbamazepine, and valproate sodium alone. Newer antiepileptic agents were administered with the aforementioned conventional antiepileptic drugs as follows: levetiracetam (n=4 with phenytoin and n=1 each with valproate sodium and phenytoin/phenobarbitone/valproate sodium), topiramate (n=1 with phenobarbitone), vigabatrin (n=1 with phenytoin/phenobarbitone), oxcarbazepine/levetiracetam (n=1 each with phenytoin and phenytoin/phenobarbitone/valproate sodium), and topiramate/lamotrigine (n=1 with phenobarbitone). A summary of the dose, route, frequency, and duration of the category A and B antiepileptic agents (phenytoin, phenobarbitone, valproate, and carbamazepine) along with the concomitant antiepileptic drugs for the various age groups are described in Table 2.

Serum levels of the antiepileptic drugs

Mean (SD) phenytoin levels amongst the study participants was 56.4 μmol/L (46.6 μmol/L) (RR = 40–80 μmol/L). Eight samples of phenytoin were observed in the toxicity range with the mean (SD) percent difference from the ULN of 37.9% (15.8%). Mean (SD) phenobarbitone serum levels was 149.9 μmol/L (71.2 μmol/L) (RR = 65–172 μmol/L). Similiar to phenytoin, 8 samples were in the toxicity range with the mean (SD) percent difference from the ULN being 28.6% (23%). Mean (SD) valproate sodium level was 259.2 μmol/L (174.3 μmol/L) (RR = 350–700 μmol/L) and none were observed to be in the toxicity range.

Changes in the liver enzymes

Liver functions were checked on daily basis for all the patients on antiepileptic drugs. None of the children had either cholestatic or mixed type of hepatic injury. Similarly, no altered liver functions were observed in patients either receiving valproate alone or in combination with phenytoin, ethosuximide, or phenobarbitone. No significant differences (P = 0.1) were observed in the proportions of patients with hepatocellular injury or liver biochemical test abnormalities between the other antiepileptic drugs (Figure 1). Similarly, none of the patients taking valproate alone or in combination with phenytoin, phenobarbitone, or ethosuximide and phenytoin/carbamazepine showed elevation of GGT, whereas 6 out of 12 (50%) taking valproate, 7 out of 9 (77.8%) taking phenobarbitone, 8 out of 10 (80%) taking phenytoin/phenobarbitone, and all the patients who received phenytoin/phenobarbitone/valproate sodium showed such elevations. No statistically significant differences were observed in the aforementioned proportions showing GGT elevations (P = 0.2).

Concomitant drugs with hepatotoxic potential

Several drugs with potential to result in hepatotoxicity were administered concomitantly with antiepileptic drugs (Table 3). Irrespective of age group, there were minimum of 2 and maximum of 15 such drugs in the study population. Due to the number of constraints, statistical analyses for the differences in LiverTox categories were carried out only for phenytoin, phenobarbitone, and phenytoin/phenobarbitone groups; and no significant differences (P values = 0.3, 0.7, and 0.6, respectively) were observed. Assessment of hepatotoxicity potential for the concomitant drug with DILLrank lead to a similar observation as summarized in Table 3. Nearly half of the concomitant drugs with hepatotoxic potential were antimicrobial drugs followed by drugs for stress ulcer prophylaxis (Table 4). However, we also observed certain differences between the LiverTox and DILLrank classifications for certain drugs (Table 5).
### Table 3
Potential hepatotoxic drugs administered with categories A/B antiepileptic drugs.

| Category A/B antiepileptic drug | Age group | Concomitant hepatotoxic drugs | Category A/B | Antiepileptic drug (n) | Age group (n) |
|---------------------------------|-----------|-------------------------------|--------------|------------------------|--------------|
| Phenobarbitone (9)              | 0–1 mo (3)| Ampicillin (C)-2; ranitidine (B)-2; cefotaxime (D)-1; cefazidime (D)-1; aceacetazolamide (D)-1; omeprazole (B)-1; cefuroxime (D)-1; ceftriaxone (B)-1; ketamine (B)-1; enoxaparin (D)-1; vancomycin (C)-1; paracetamol (T)-1; meropenem (D)-1 | B-5; C-3; D-6; T-1 | MC,8-1; LC,5-4; LC,4-2; LC,3-5; LC,0-2 | 3 (2–6) |
|                                 | 1 mo–2 y (3)| Ampicillin (C)-1; cefotaxime (D)-1; acyclovir (D)-2; vancomycin (C)-2; omeprazole (B)-2; ceftriaxone (B)-1; metronidazole (C)-2; paracetamol (T)-2; amoxicillin–clavulanate (A)-1; meropenem (D)-1 | A-1; B-3; C-5; D-3; T-2 | LC,5-2; LC,4-3; LC,3-4; LC,0-1 | 4 (4–5) |
|                                 | 2–12 y (3)| Paracetamol (T)-2; amoxicillin–clavulanate (A)-1; lamotrigine (B)-1; topiramate (C)-2; cefazidime (D)-1; omeprazole (B)-1; clonazepam (D)-1; ranitidine (B)-2; cefotaxime (D)-2; clindamycin (B)-1; cepfeme (D)-1; fluconazole (B)-1 | A-1; B-6; C-2; D-5; T-2 | MC,8-1; MC,7-1; LC,5-5; LC,4-1; LC,3-6 | 3 (3–9) |
| Phenytoin (12)                  | 0–1 mo (1)| Amiodarone (A)-1; paracetamol (T)-1; meropenem (D)-1; omeprazole (B)-1; enoxaparin (D)-1; ampicillin (C)-1; cefazidime (D)-1 | A-1; B-1; C-1; D-3; T-1 | MC,8-1; LC,5-1; LC,4-1; LC,3-3 | 6 |
|                                 | 1 mo–2 y (3)| Paracetamol (T)-3; mebendazole (D)-1; ketamine (B)-1; ranitidine (B)-1; vancomycin (C)-1; fluconazole (B)-1; metronidazole (C)-1; levetiracetam (C)-1; ceftriaxone (B)-3; omeprazole (B)-3; enoxaparin (D)-1; cimetidine (B)-1; baclofen (D)-1; nifidpine (B)-1; ciprofloxacin (B)-1; meropenem (D)-1 | B-12; C-3; D-4; T-3 | MC,8-2; LC,8-1; LC,5-1; LC,4-6; LC,3-6; LC,2-1; LC,0-2 | 7 (3–8) |
|                                 | 2–12 y (8)| Paracetamol (T)-5; hydroxyurea (C)-1; omeprazole (B)-5; meropenem (D)-5; amoxicillin (B)-1; fluconazole (B)-2; clindamycin (B)-3; levetiracetam (C)-3; ceftriaxone (B)-2; vancomycin (C)-3; acyclovir (D)-1; ranitidine (B)-1; ketamine (B)-1; cefazidime (D)-2; ondansetron (D)-2; captopril (B)-2; nifedipine (D)-2; acetazolamide (D)-1; cefpeme (D)-1; amloidine (C)-1; labetalol (C)-2; risperidone (C)-1; atenolol (D)-1; trimetoprim–sulfamethoxazole (A)-1; voriconazole (B)-1; etoposide (C)-1; metronidazole (C)-1; cefazidime (D)-1 | A-1; B-18; C-13; D-9; T-5 | MC,8-6; LC,8-3; LC,7-4; LC,5-4; LC,4-9; LC,3-14; LC,0-4 | 4 (3–15) |
| Valproate sodium (2)            | 2–12 y (2)| Omeprazole (B)-2; vancomycin (C)-1; paracetamol (T)-1; levetiracetam (C)-1; ceftriaxone (B)-1; clindamycin (B)-1 | B-4; C-2; T-1 | LC,8-1; LC,4-4; LC,0-1 | 3 |

(continued on next page)
| Category A/B antiepileptic drug | Age group | Concomitant hepatotoxic drugs | Category A/B | Antiepileptic drug (n)* | Age group (n)** |
|--------------------------------|-----------|------------------------------|--------------|------------------------|---------------|
| Phenobarbitone/valproate (10)  | 0–1 mo (1)| Ampicillin (C)-1; meropenem (D)-1; omeprazole (B)-1 | B-1; C-1; D-1 | LC;3-2; LC;4-1 | 4 |
|                                | 1 mo–2 y (8)| Ibuprofen (A)-1; ranitidine (B)-5; atenolol (B)-2; acetzolamide (D)-1; ampicillin (C)-3; cefazidime (D)-1; meropenem (D)-3; vancomycin (C)-4; paracetamol (T)-2; ceftriaxone (B)-4; cefuroxime (D)-2; hydralazine (A)-3; labetalol (C)-2; nifedipine (B)-2; captopril (B)-1; omeprazole (B)-3; cefuroxime (D)-1; cefotaxime (D)-1; cefotaxime (C)-1; omperazole (B)-1 | A-5; B-19; C-9; D-10; T-2 | LC;3-12; LC;2-1; LC;0-5 | 6 (3-9) |
|                                | 2–12 y (1)| Clonazepam (D)-1; acetzolamide (D)-1; paracetamol (T)-1; vancomycin (C)-1; fluconazole (B)-1; cefepime (D)-1; omeprazole (B)-1; ciprofloxacin (B)-1; meropenem (D)-1; sildenafil (D)-1; cefazidime (D)-1 | B-3; C-1; D-6; T-1 | MC;8-2; MC;7-1; LC;3-5; LC;4-1; LC;0-1 | 9 |
| Phenobarbitone/valproate (3)   | 2–12 y (3)| Meropenem (D)-2; vancomycin (C)-2; levetiracetam (C)-2; omeprazole (B)-2; ketamine (B)-1; cefazidime (D)-1; fluconazole (B)-1; nifedipine (B)-1; ranitidine (B)-1; cefepime (D)-1; captopril (B)-1; paracetamol (T)-1; aspirin (T)-1; ceftriaxone (B)-1; acetylco (D)-1 | B-8; C-4; D-3; T-2 | MC;8-1; LC;7-2; LC;5-1; LC;4-2; T-1 | 7 (6–11) |
| Phenobarbitone/valproate (1)   | 2–12 y (1)| Ketamine (B)-1; labetalol (C)-1; hydralazine (B)-1; ceftriaxone (B)-1; paracetamol (T)-1; acetylco (D)-1; atenolol (D)-1; amiodarone (C)-1; ceftriaxone (D)-1; enalapril (D)-1 | B-3; C-2; D-4; T-1 | MC;8-1; LC;7-2; LC;5-1; LC;4-2; T-1 | 8 |
| Phenytoin/valproate sodium (2) | 2–12 y (2)| Amoxicillin–calvulanate (A)-1; acetylco (D)-1; ranitidine (B)-2; paracetamol (T)-2; levetiracetam (C)-1; cefotaxime (D)-1 | A-1; B-2; C-1; D-2; T-2 | LC;8-1; LC;5-4 | 4.5 (4–5) |
| Carbamazepine/phenytoin (1)    | 2 y       | Omeprazole (B)-1; ceftriaxone (B)-1; clindamycin (B)-1; paracetamol (T)-1; ibuprofen (A)-1; cefazidime (D)-1; clonazepam (D)-1; ondansetron (D)-1 | A-1; B-3; D-2; T-1 | LC;7-1; LC;4-2; LC;3-4 | 8 |
| Valproate/ethosuximide (1)     | 2–12 y (1)| Clonazepam (B)-1; omeprazole (B)-1; vancomycin (C)-1; clindamycin (B)-1; cefazidime (D)-1; levetiracetam (C)-1; fluconazole (B)-1 | B-3; C-2; D-2 | MC;8-1; LC;8-1; LC;5-1; LC;4-1; LC;3-2; LC;0-1 | 7 |

DILI = drug-induced liver injury; HCTZ = hydrochlorothiazide; MC = most-DILI concern; LC = less-DILI concern.

* LiverTox (https://livertox.nih.gov), a database conceptualized by the National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases and the Drug-Induced Liver Injury Network study group.

† Classified between 0 and 8 according to Food and Drug Administration.

‡ Excluded the category T because this class of drug is likely to result in DILI only at high doses.
Figure 1. Hepatocellular injury and liver biochemical test abnormalities among the study participants. No significant differences were observed in the proportion of patients with any of the types of liver injury between the antiepileptic drugs.

Table 4
Total number of concomitant drugs with potential hepatotoxicity amongst the study cohort.

| Drug class (%) | Drug | LiverTox category | DILIrank concern; severity class | No. of children (%) |
|----------------|------|-------------------|---------------------------------|--------------------|
| Antimicrobials (56.1%) | Acyclovir | D | Not classified | 8 (4.4) |
| | Amoxicillin-clavulanate | A | Not classified | 3 (1.7) |
| | Ampicillin | C | LC; 3 | 8 (4.4) |
| | Cefepine | D | LC; 3 | 4 (2.2) |
| | Cefotaxime | D | LC; 5 | 10 (5.6) |
| | Ceftazidime | D | LC; 3 | 7 (3.9) |
| | Ceftriaxone | B | LC; 4; 5 | 15 (8.3) |
| | Clindamycin | B | LC; 3 | 7 (3.9) |
| | Fluconazole | B | MC; 8 | 7 (3.9) |
| | Meropenem | D | LC; 3 | 9 (5) |
| | Metronidazole | C | LC; 3 | 7 (3.9) |
| | Vancomycin | C | LC; 0 | 16 (8.9) |
| Drugs for SUP (21.1%) | Omeprazole | B | LC; 4 | 24 (13.3) |
| Cardiovascular drugs (17.8%) | Ranitidine | B | LC; 5 | 14 (7.8) |
| | Atenolol | D | LC; 4 | 4 (2.2) |
| | Captopril | B | LC; 7 | 5 (2.8) |
| | Enoxaparin | D | LC; 3 | 3 (1.7) |
| | Hydralazine | B | LC; 3 | 4 (2.2) |
| | Labetalol | C | MC; 8 | 6 (3.3) |
| | Nifedipine | B | LC; 3 | 6 (3.3) |
| Others (5) | Acetazolamide | D | MC; 8 | 4 (2.2) |
| | Ketamine | B | LC; 0 | 6 (3.3) |
| | Ondansetron | D | LC; 7 | 3 (1.7) |

DILI = drug-induced liver injury; LC = Less-DILI concern; MC = Most-DILI concern; SUP = stress ulcer prophylaxis.
* LiverTox (https://livertox.nih.gov), a database conceptualized by the National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases and the Drug-Induced Liver Injury Network study group.
† Total number may exceed the total sample included because each child received multiple drugs.

Multivariable logistic regression analysis

A multivariable logistic regression model was developed for predicting the risk of hepatocellular injury or liver biochemical test abnormalities compared with children with normal liver enzymes (Table 6). Presence of concomitant category B hepatotoxic drugs (odds ratio = 2; 95% CI, 1–3.3) and toxic drug levels (odds ratio = 10; 95% CI, 1.4–1000) were associated with increased risks of DILI. A similar regression model for DILIrank categories was developed and none of the evaluated factors were observed to be statistically significant (Table 7) although a trend was noted for the number of less-DILI-concern concomitant drugs (P = 0.06) and toxic drug levels (P = 0.09).

Discussion

We carried out the present study to assess the incidence and the associated factors for DILI in critically ill children receiv-
ing antiepileptic drugs. Five out of 9 patients taking phenobarbitone (55.6%), 9 out of 12 taking phenytoin monotherapy (75%), 7 out of 10 taking phenytoin/phenobarbitone (70%), all 3 receiving phenytoin/phenobarbitone/valproate sodium, and 1 with phenytoin/carbamazepine developed DILI either in the form of hepatocellular injury or liver biochemical test abnormalities. None of the patients had cholestatic or mixed type of liver injuries. Similar number of patients receiving each of the above antiepileptic drug/s also showed elevations of GGT. Minimum 2 drugs with hepatotoxic potential were identified concomitantly with antiepileptic agents. Concomitant category B hepatotoxic drugs and toxic drug levels were associated with significantly increased risks of DILI with antiepileptic drugs. Similarly, a trend was observed for the less-DILI-concern concomitant class of drugs and toxic drug levels per DILIRank classification. Differences might exist between the DILIRank and LiverTox classifications of drugs that needs further exploration.

Sepsis and respiratory infections are the most common causes for admissions and consequent mortality in PICUs. Antimicrobial agents such as third-generation cephalosporins (eg, cefotaxime, ceftriaxone, and ceftazidime), aminopenicillins, aminoglycosides, meropenem, and vancomycin are commonly used in critically ill children in ICUs. We observed similar antimicrobial agents used in our study participants. With the exception of aminoglycosides, all other groups of antimicrobial drugs have been documented with DILI. Surprisingly, antimicrobial agents constitute the major class of drugs causing DILI as well as chronic liver damage according to registry studies. Antiepileptic drugs classes are the second leading group of implicated in causing DILI. Hence, the risk of DILI is certainly higher when such drug combinations are used out of necessity in PICUs. In the present study, we observed that all critically ill children received at least 1 antimicrobial drug with hepatotoxic potential. Similarly, drugs used for stress ulcer prophylaxis (SUP) such as ranitidine and omeprazole are also potentially hepatotoxic and should better be avoided at least in a most-DILI-concern as per DILIRank or category A LiverTox antiepileptic drug is administered to critically ill children. A recent network meta-analysis refuted any therapeutic benefits with all the drug classes that are used for SUP in critically ill adults, but there is dearth of evidence in pediatric populations. Sucralfate is as efficacious as proton pump inhibitors and histamine-2 receptor blockers for SUP at least in reducing the overt upper gastrointestinal bleeding. Sucralfate is a no-DILI-concern drug according to DILIRank classification and so shall be considered as a safe alternative to other drugs for SUP in critically ill children receiving antiepileptic drugs with greater risks of hepatotoxicity. With regard to the antimicrobial drugs, the choice is limited owing to the development of widespread resistance. On the other hand, most of the recent antiepileptic agents such as levetiracetam, lamotrigine, lacosamide, oxcarbazepine, pregabalin, gabapentin, and vigabatrin are associated with lower risks of DILI, and on considering the framework of similar efficacy to conventional antiepileptic drugs, should be preferred over the first-line antiepileptic drugs in children admitted into ICUs receiving concomitant drugs with hepatotoxic potential. Levetiracetam and lacosamide are also available intravenously and can be alternatives in status epilepticus. A systematic review estimated that the efficacy of levetiracetam as an alternative to phenytoin in status epilepticus ranges between 44% and 94%. A recent randomized clinical trial in children concluded that levetiracetam is equivalent to phenytoin in status epilepticus. Hence, such drugs shall be preferred over the conventional antiepileptic agents in children at high-risk for DILI.

DILI from antiepileptic drugs can be either idiosyncratic or dose-related. Idiosyncratic reactions are more common with the aromatic ring containing antiepileptic agents such as carba-

### Table 5

Discrepancies between the LiverTox™ and drug-induced liver injury (DILI) rank classifications in classifying certain concomitant drugs in the study participants.

| Drug                          | LiverTox category | DILIRank classification | DILI concern | Severity class |
|-------------------------------|-------------------|--------------------------|--------------|----------------|
| Acetazolamide                 | D                  | Most 8                   |              |                |
| Acyclovir                     | D                  | Not mentioned            |              |                |
| Amoxicillin-clavulanate       | A                  | Only amoxicillin has been categorized as less-DILI concern and the severity class is 5. There is no mention for amoxicillin-clavulanate |              |                |
| Divalproex sodium             | Not categorized    | Most 8                   |              |                |
| Hydraldazine                  | A                  | Less 3                   |              |                |
| Labetalol                     | C                  | Most 8                   |              |                |
| Trimethoprim-sulfamethoxazole | A                  | Only trimethoprim has been categorized as less-DILI concern with the severity class 4. There is no mention for trimethoprim-sulfamethoxazole |              |                |

* LiverTox (https://livetox.nih.gov), a database conceptualized by the National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases and the Drug-Induced Liver Injury Network study group.

### Table 6

Summary results of multivariable logistic regression analysis for the factors predicting the risk of hepatocellular injury and liver biochemical abnormalities with LiverTox™ categories of antiepileptic drugs.

| Predictive factors | Hepatocellular injury/LBA1 |
|--------------------|----------------------------|
| Category A concomitant hepatotoxic drugs | 1.93 (0.98–3.91); 0.06 |
| Category B concomitant hepatotoxic drugs | 2.66 (1.26–5.61); 0.01 |
| Age group: 0–1 mo* | 0.00 (0.00–1.00); 0.03 |
| Age group: 1 mo–2 y† | 0.02 (0.01–0.03); 0.02 |
| Male sex‡ | 0.99 (0.63–1.55); 0.99 |
| Category B antiepileptic drugs§ | 1.09 (0.50–2.36); 0.86 |
| Category A/B antiepileptic drugs¶ | 1.09 (0.50–2.36); 0.86 |
| Category A antiepileptic drugs‖ | 1.09 (0.50–2.36); 0.86 |
| Drug level in the toxic range¶ | 0.00 (0.00–1.00); 0.00 |

LBA — liver biochemical test abnormalities; ND — not determined.

1 LiverTox (https://livetox.nih.gov), a database conceptualized by the National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases and the Drug-Induced Liver Injury Network study group.

* Values are presented as odds ratio [95% CI]; P value.
† In reference to age group 2–12 y.
‡ In reference to female sex.
§ In reference to most-DILI-concern antiepileptic monotherapy.
¶ In reference to those drug levels in the normal range.
mazapine, phenytoin, and phenobarbital and valproate.27 We observed a greater risk of DILI with the antiepileptic drug levels in the toxicity range. Dose-DILI effect relationship has been well elucidated based on the quantum of metabolites especially for valproate sodium.28 Polymorphisms in certain metabolizing enzymes were identified to be associated with antiepileptic agents-induced DILI.29 Future studies should focus on identifying individuals with high-risk alleles predisposing DILI in critically ill patients. It is a great challenge for the treating physicians to maintain conventional antiepileptic agents within a narrow therapeutic window.30 The recent antiepileptic agents have an advantage in this regard and shall be an alternative for children with unstable levels of conventional antiepileptic drugs.

The study is limited in not following up with the status of liver enzymes in patients after their transfer out from ICU; baseline duration of antiepileptic therapy was not available, and scores for assessing the severity of illness could not be used as complete details required for such scorings were not available from the hospital records.

Conclusions

We observed significant proportion of critically ill children who are taking antiepileptic drugs experience DILI either in the form of hepatocellular injury or liver biochemical test abnormalities. Guidelines recommending concomitant drugs with less/absent risk of potential hepatotoxicity in children admitted into ICUs who are receiving antiepileptic agents are the need of the hour.

Declaration of Competing Interest

The authors have indicated that they have no conflicts of interest regarding the content of this article.

Acknowledgment

The authors thank the Research Technical Support Team, Ministry of Health, Bahrain, for their approval and continued oversight during the conduct of the study. Dr Kannan Sridharan was responsible for conceptualization of the study, the formal analysis, methodology, project administration, software, and writing the original draft. Dr Kannan Sridharan, Dr Amal Al Daylamy, Dr Reema Ajwai and Dr Husain Al Ajoor performed data curation and were responsible for the investigation, gathering resources, and review and editing of the manuscript.

References

1. Vorderwülbecke BJ, Lichtner G, von Dincklage F, Holthkamp M. Acute antiepileptic drug use in intensive care units. J Neurol. 2018;265:2841–2850.
2. Yerram S, Katyal N, Premkumar K, Nattanmai P, Newey CR. Seizure prophylaxis in the neuroscience intensive care unit. J Intensive Care. 2018;6:17.
3. Sahin S, Yazici MU, Ayar G, Karakol ZS, Arhan EP. Seizures in a Pediatric Intensive Care Unit: A Prospective Study. J Trop Pediatr. 2016;62:94–100.
4. Valencia J, Lozano G, Kothare SV, Melvin JJ, Khurana DS, Hardison HH, Yum SS, Legido A. Epileptic seizures in the pediatric intensive care unit setting. Epileptic Disord. 2006;8:277–284.
5. Hussein RRS, Soliman RH, Ali AMA, Tawfeik MH, Abdelrahem MEA. Effect of antiepileptic drugs on liver enzymes. Beni-Suef University Journal of Basic and Applied Sciences. 2013;2:14–19.
6. Devabhavi H. An Update on Drug-induced Liver Injury. J Clin Exp Hepatol. 2012;2:247–259.
7. Shi Q, Yang X, Greenhaw JI, Salminen AT, Russotti GM, Salminen WF. Drug-induced liver injury in children: Clinical observations, animal models, and regulatory status. Int J Toxicol. 2017;36:365–379.
8. Aleppey T, Zec S, Milosavljevic T. Drug-induced liver injury: Do we know everything? World J Hepatol. 2017;9:491–502.
9. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43:53–59.
10. Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012;18:249–257.
11. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29:337–347.
12. Koch A, Streetz K, Tischendorf J, Trautwein C, Tacke F. Abnormal liver function tests in the intensive care unit. Med Klin Intensivmed Notfmed. 2013;108:599–608.
13. Lescot T, Karvellas C, Beausser M, Magder S. Acquired liver injury in the intensive care unit. Anesthesiology. 2012;117:898–904.
14. Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, Hu P, Hu XQ, Jia JD, Lai RT, Li DL, Liu YY, Lu LG, Ma SW, Ma X, Nan YM, Ren H, Shen T, Wang H, Wang JY, Wang TL, Wang XJ, Wei L, Xie Q, Xie W, Yang CQ, Yang DL, Yu YY, Zeng MD, Zhang L, Zhao XF, Zhuang XH Chinese Medical Association (CMA). CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221–241.
15. Lisi DM. Drug-induced liver injury: An overview. US Pharm. 2016;40:31–34.
16. Björansson ES. Hepatotoxicity by drugs: The most common implicated agents. Int J Mol Sci. 2010;11:723–734.
17. Paediatric age categories to be used in differentiating between listing on a model essential medicines list for children. World Health Organization. Available at: http://archives.who.int/eme/excpom/children/Tems/ PositionPaper/Ag.Measure.pdf [Accessed on 28 April 2019].
18. Siddiqui NU, Afrad Z, Ijaz H, Haque A. Mortality patterns among critically ill children in a Pediatric Intensive Care Unit of a developing country. Indian J Crit Care Med. 2015;19:147–150.
19. Biebele I, Alberti CS, Bowen JR, Roberts CL. Pediatric admissions that include intensive care: a population-based study. BMC Health Serv Res. 2018;18:264.
20. Grohskopf LA, Huskins WC, Sinkwitz-Cochran RL, Levine GI, Goldmann DA, Jarvis WR. Pediatric Prevention Network. Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J. 2005;24:766–773.
21. Blinova E, Lau E, Bitun A, Cox P, Schwartz S, Arenafo E, Yau Y, Streitenberger L, Paschuram CS, Marshall J, Seto W. Point prevalence survey of antimicrobial utilization in the cardiac and pediatric critical care unit. Pediatr Crit Care Med. 2013;14:e260–e268.
22. Andrade RJ, Lucena MI, Kaplowitz N, García-Muñoz B, Borraz Y, Pachkoria K, García-Cortés M, Fernández MC, Pelaez G, Rodrigo L, Durán JA, Costa J, Planas R, Barrocasal A, Guarnier C, Romero-Gomez M, Mupyo-Yagie T, Salmerón J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581–1588.
23. Devabhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. Semin Liver Dis. 2014;34:145–151.
24. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21:648–653.
25. Vidaurroz J, Gedela S, Varioso S. Antiepileptic Drugs and Liver Disease. Pediatr Neurol. 2017;77:23–36.
26. Sridharan K, Sivarangamkiran G, Gnanaraj J. Pharmacological interventions for stress ulcer prophylaxis in critically ill patients: a mixed treatment comparison network meta-analysis and a recursive cumulative meta-analysis. Expert Opin Pharmacother. 2018;19:151–158.
27. Zeleno J, Kuimiien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure. 2012;21:233–236.
28. Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, Woolfall K, Roper L, Noble J, Lee ED, Potter S, Tate P, Iyer A, Evans V, Appleton R. Paediatric Emergency Research in the United Kingdom & Ireland (PE- PEARI) collaborative. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (ECLIPSE): a multicentre, open-label, randomised trial. Lancet. 2019 Apr 17 pii: S0140-6736(19)30724-X.
29. Bryant AE, Dreffuss AE. Hepatotoxicity associated with antiepileptic drug therapy. CNS Drugs. 1995;4:399–413.
30. Björansson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008;118:281–290.